UTMD's top line has contracted for roughly nine consecutive quarters, with 2026Q3 revenue down 12.1% year over year to $8.6M, yet gross margin expanded to 60.6% in 2026Q1 and operating margin has held between 26.6% and 33.4%, suggesting pricing or mix discipline is offsetting volume weakness.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 22, 2026 | $0.88 vs — | $9M vs — |
Q3 2026 Jul 23, 2026 | $0.84 vs — | $9M vs — |
Q2 2026 Apr 23, 2026 | $0.82 vs — | $9M vs — |
Q1 2026 Jan 29, 2026 | $0.80 vs — | $9M vs — |
Utah Medical's Q3 earnings per share rise 7% year over year despite a 12.1% revenue decline, aided by lower operating expenses. Management expects a smaller revenue decline for full-year 2026.
SALT LAKE CITY, UT / ACCESS Newswire / October 22, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2026 financial results that include changes from the prior year's same period results. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.
SALT LAKE CITY, UT / ACCESS Newswire / October 5, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The Offer was initially scheduled to expire at 5:00 p.m.
Benchmark UTMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Utah Medical Products, Inc. (UTMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $72.23 | $229.98M | 21.58 | -5.83% | 30.48% | 8.78% | 1.7% | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $87.23 | $5.2B | 32.89 | 11.66% | 9.94% | 9.65% | — | |
| $80.89 | $1.85B | 29.47 | 13.53% | 23.51% | 15.33% | 0.98% | |
| $11.73 | $484.83M | -14.97 | 9.46% | -10.12% | -19.25% | — | |
| $16.91 | $1.16B | -23.92 | 7.93% | -4.58% | -35.61% | — |
Utah Medical Products, Inc. (UTMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Utah Medical Products, Inc. (UTMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 22, 2026·SEC
Jul 23, 2026·SEC
May 4, 2026·SEC
Get notified when UTMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Utah Medical Products, Inc. (UTMD) stock FAQ — growth, dividends, profitability & financials explained
Utah Medical Products, Inc. (UTMD) reported $34.9M in revenue over the trailing twelve months. Revenue was $38.5M in fiscal year 2025. That is 0% less than the $38.7M of fiscal year 1996.
Utah Medical Products, Inc. (UTMD) revenue fell by 9.6% over the trailing twelve months, compared with the twelve months before.
Yes. Utah Medical Products, Inc. (UTMD) earned $10.6M in net income over the trailing twelve months (a 30.5% net margin).
Yes. Utah Medical Products, Inc. (UTMD) pays a dividend that yields 1.70% at the current price, a moderate yield.
Utah Medical Products, Inc. (UTMD) had a return on equity (ROE) of 8.8% over the trailing twelve months. That is below the market's typical 10-15%.
Utah Medical Products, Inc. (UTMD) generated $7.6M in free cash flow over the trailing twelve months.
